Education
About Us
Working with TipRanks
Follow Us
Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
MNPR Stock Chart & Stats
$67.04
-$0.61(-2.42%)
At close: 4:00 PM EST
$67.04
-$0.61(-2.42%)
Day’s Range― - ―
52-Week Range$24.00 - $105.00
Previous CloseN/A
Volume23.12K
Average Volume (3M)264.86K
Market Cap
$465.11M
Enterprise Value$438.20M
Total Cash (Recent Filing)$143.68M
Total Debt (Recent Filing)$102.24K
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Mar 19, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding6,682,584
10 Day Avg. Volume327,504
30 Day Avg. Volume264,856
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)0.00
P/FCF Ratio-13.02
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.87
Forecast
1Y Price Target
$112.91Price Target Upside68.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyPositive late‑stage trial results showing meaningful copper mobilization and sustained neurological improvement alongside a favorable safety profile could increase the probability of regulatory approval and clinician interest.
Differentiation And Commercial OpportunityOnce‑daily oral dosing and a mechanism distinct from traditional chelators, combined with a multi‑billion dollar addressable market for Wilson disease, could drive significant commercial upside if regulatory acceptance and physician uptake occur.
Regulatory Data And AnalysisA comprehensive re‑analysis demonstrating net‑negative copper balance through increased fecal excretion, supported by new animal data, directly addresses earlier methodological concerns and strengthens the case for an NDA submission.
Bears Say
Market Adoption And ReimbursementEntrenched prescribing habits, preference for cheaper standard therapies, and the absence of peer‑reviewed publication of key copper balance data could limit physician adoption and reimbursement, constraining commercial uptake.
Program History And Scientific ControversyA complex development history and divergent expert opinions on the mechanism and long‑term safety create reputational and regulatory hurdles that could complicate approval and execution of the program.
Regulatory UncertaintyRegulatory feedback could include requests for additional data or labeling negotiations, creating material uncertainty around the approval timeline and ultimate labeling terms.
Monopar Therapeutics Inc News
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $24.00 and its highest was $105.00 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $465.11M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Mar 19, 2026 which is in 62 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.387 by -$0.093.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -0.48.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,682,584 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.387. Following the earnings report the stock price went up 5.364%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monopar Therapeutics Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$112.91 (68.42% Upside)
$112.91 (68.42% Upside)
Blogger Sentiment
Neutral
MNPR Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 224.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $239.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
160.95%
12-Months-Change
Fundamentals
Return on Equity
-26.54%
Trailing 12-Months
Asset Growth
2275.71%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
MNPR Stock 12 Month Forecast
Average Price Target
$112.91
▲(68.42% Upside)
Technical Analysis
Cardiff Oncology
―
Vanda
―
Verastem
―
Mereo Biopharma Group Plc
―
Silence Therapeutics
―